【佳学基因检测】17q24 rs1859962 基因多态性与前列腺癌风险的关系：基因检测证据

dota2吧雷电竞 基因检测费17800说明

开会学习医学博士年度肿瘤汇报《肿瘤基因易感位点列表及发生率分析》，分析了《Medicine (Baltimore)》在. 2020 Jan;99(3):e18398.发表了一篇题目为《17q24 rs1859962 基因多态性与前列腺癌风险的关联：系统评价和荟萃分析》前列腺风险基因检测的临床研究文章。该研究由Feiqiang Ren, Peihai Zhang, Ziyang Ma, Ling Zhang, Guangsen Li, Xiaopeng Huang, Degui Chang, Xujun Yu等完成。促进了前列腺癌遗传性的研究，丰富了前列腺癌基因信息与肿瘤易感性之间的关系。

前列腺癌dota2吧雷电竞 及正确治疗临床研究内容关键词：

前列腺癌,多态性,风险,大数据分析,人工智能分析

前列腺癌靶向治疗基因检测临床应用结果

基因解码基因检测的研究介绍：贼近，几项全基因组关联研究表明，17q24 rs1859962 基因变异与前列腺癌 (PCa) 风险存在累积关联，但在此问题上的基因检测的研究结果相互矛盾。因此，基因解码基因检测进行了系统的大数据分析及人工智能算法，以评估 17q24 rs1859962 基因与前列腺癌风险之间的关联。基因解码基因检测的研究方法：使用 PubMed、EMBASE、Science Direct/Elsevier、CNKI 和 Cochrane 图书馆进行系统文献检索，直至 1 月2019 年关注 17q24 rs1859962 基因多态性与前列腺癌风险相关性的研究。使用 Review Manager 和 stata 软件进行大数据分析。在随机或固定效应模型中以 95% 置信区间 (95% CI) 确定联合 OR。基因解码基因检测的研究结果：确定了 8 项研究，包括 7863 例前列腺癌患者和 17122 例正常对照。基因解码基因检测的基因解码基因检测的研究结果揭示了所有遗传模型中 17q24 rs1859962 基因多态性与前列腺癌之间的显着关联（P < 0.05）。综合优势比和 95% 置信区间如下： 加法模型（优势比 [ORs] 1.44, 95%，置信区间 [CI] [1.32, 1.57]）；共显性模型（ORs 1.22, 95% CI [1.08, 1.39]）；主导模型（ORs 1.25, 95%, CI [1.17, 1.34]）；隐性模型（ORs 1.27, 95% CI [1.18, 1.36]）；等位基因模型（ORs 1.32, 95% CI [1.12, 1.55]）。基因解码基因检测的研究结论：本研究支持 17q24 基因 rs1859962 与前列腺癌进展之间的拟议关联。具体而言，该多态性被认为是前列腺癌的危险因素。然而，需要更大样本量的研究来更好地阐明 17q24 rs1859962 基因多态性与前列腺癌之间的相关性。

肿瘤发生与反复转移国际数据库描述：

Background: Recently, several genome-wide association studies have demonstrated a cumulative association of 17q24 rs1859962 gene variants with prostate cancer (PCa) risk, but conflicting results on this issue have been reported. Hence, we performed a systematic literature review and meta-analysis to assess the association between 17q24 rs1859962 gene and PCa risk.Methods: Systematic literature searches were conducted with PubMed, EMBASE, Science Direct/Elsevier, CNKI, and the Cochrane Library up to January 2019 for studies focusing on the association of 17q24 rs1859962 gene polymorphism with PCa risk. Meta-analysis was performed with Review Manager and stata software. Combined OR were identified with 95% confidence intervals (95% CI) in a random or fixed effects model.Results: Eight studies were identified, including 7863 cases of PCa patients and 17122 normal controls. Our results revealed significant associations between the 17q24 rs1859962 gene polymorphism and PCa in all genetic models (P < 0.05). The combined odds ratios and 95% confidence intervals were as follows: Additive model (odds ratios [ORs] 1.44, 95%, confidence interval [CI] [1.32, 1.57]); Codominant model (ORs 1.22, 95% CI [1.08, 1.39]); Dominant model (ORs 1.25, 95%, CI [1.17, 1.34]); recessive model (ORs 1.27, 95% CI [1.18, 1.36]); allele model (ORs 1.32, 95% CI [1.12, 1.55]).Conclusion: The present study supports the proposed association between the 17q24 gene rs1859962 and PCa progression. Specifically, this polymorphism is suggested to be a risk factor of PCa. However, studies with larger sample sizes are needed to better illuminate the correlation between 17q24 rs1859962 gene polymorphism and PCa.